Drugs / HWK-016
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07470853 | Mar 2026 → Feb 2028 expected | endometrial cancer | Whitehawk Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HWK-016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07470853 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT07470853 ↗ |